The COVID-19 pandemic has affected more than 21 million individuals around the world,
with over 750,000 deaths. A large body of evidence suggests that COVID-19 is associated …

Background Patients with coronavirus disease 2019 (COVID-19) infections often have
macrovascular or microvascular thrombosis and inflammation, which are known to be …

Background: Antithrombotic treatment, including low molecular weight heparin (LMWH) or
unfractionated heparin (UFH), has been proposed as a potential therapy for coronavirus …

Recent publications have questioned the efficacy of using therapeutic or intermediate doses
of low molecular weight heparin in COVID-19 patients, especially in the most severe …

Purpose The optimal amount of anticoagulation for critically ill COVID-19 patients is
controversial. Therefore, we aimed to evaluate the efficacy and safety of escalated doses of …

Moll et al. recently published a retrospective analysis of COVID-19 patients admitted to
intensive care unit (ICU) from a single tertiarycare academic hospital showing that there was …

Objectives To compare mortality of hospitalized COVID-19 patients under two low–
molecular weight heparin (LMWH) thromboprophylaxis strategies: standard dose and …

Arterial and venous thrombotic events in COVID-19 cause significant morbidity and mortality
among patients. Although international guidelines agree on the need for anticoagulation, it …

Background We carried out a meta-analysis since there is not enough evidence to
recommend for or against therapeutic-dose anticoagulation compared with …

COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and
extra-pulmonary complications; in particular, it may predispose to thromboembolic disease …